With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.94-91-7,N,N’-Bis(salicylidene)-1,2-propanediamine,as a common compound, the synthetic route is as follows.
A mixture of H2salipn (28.2mg, 0.100mmol) and [Ru(PPh3)3Cl2] (95.8mg, 0.100mmol) inTHF (30mL) was refluxed with stirring for 6 h, during which there was a color changefrom brown to dark green. The solvent was evaporated in vacuo, and the residue waswashed with diethyl ether (5mL 2) and hexane (5mL 2). Recrystallization fromCH2Cl2/hexane afforded black block crystals of 11.5CH2Cl2 in 7 days. Yield: 33.4mg,55.6% (based on Ru). IR (KBr disc, cm-1): 1594 (C=N), 1314 (Ar-O); MS (FAB): m/z 679[M], 644 [M – Cl], 417 [M – PPh3]. Anal. Calcd. for C35H31N2O2PClRu1.5(CH2Cl2) (%): C,54.41; H, 4.26; N, 3.48. Found: C, 54.47; H, 4.23; N, 3.50.
94-91-7 N,N’-Bis(salicylidene)-1,2-propanediamine 7210, achiral-catalyst compound, is more and more widely used in various.
Reference£º
Article; Ji, Jiao; Chen, Xin; Wang, Chang-Jiu; Jia, Ai-Quan; Zhang, Qian-Feng; Journal of Coordination Chemistry; vol. 72; 3; (2019); p. 480 – 490;,
Chiral Catalysts
Chiral catalysts – SlideShare